Natera, Inc.
NASDAQ:NTRA
167.39 (USD) • At close September 8, 2025
Overzicht | Financiële gegevens
| Bedrijfsnaam | Natera, Inc. |
| Symbool | NTRA |
| Munteenheid | USD |
| Prijs | 167.39 |
| Beurswaarde | 22,973,942,720 |
| Dividendpercentage | 0% |
| 52-weken bereik | 114.62 - 183 |
| Industrie | Diagnostics & Research |
| Sector | Healthcare |
| CEO | Mr. Steven Leonard Chapman |
| Website | https://www.natera.com |
An error occurred while fetching data.
Over Natera, Inc.
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)







